OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany.

Ziemssen, Tjalf; Richter, Stephan; Mäurer, Mathias; Buttmann, Mathias; Kreusel, Boris; Poehler, Anne-Maria; Lampl, Maren; Linker, Ralf A

Ziemssen, Tjalf; Richter, Stephan; Mäurer, Mathias; Buttmann, Mathias; Kreusel, Boris; Poehler, Anne-Maria; Lampl, Maren; Linker, Ralf A.

Afiliación

Ziemssen T; Department of Neurology, Center of Clinical Neuroscience, Carl Gustav Carus University Clinic, University Hospital of Dresden, Dresden, Germany.
Richter S; Mind MVZ, Center of Neurology, Stuttgart, Germany.
Mäurer M; Department of Neurology, Klinikum Würzburg Mitte, Würzburg, Germany.
Buttmann M; Department of Neurology, Caritas Hospital Bad Mergentheim, Bad Mergentheim, Germany.
Kreusel B; Bristol Myers Squibb GmbH & Co. KGaA, Munich, Germany.
Poehler AM; Bristol Myers Squibb GmbH & Co. KGaA, Munich, Germany.
Lampl M; Bristol Myers Squibb GmbH & Co. KGaA, Munich, Germany.
Linker RA; Department of Neurology, University Hospital of Regensburg, Regensburg, Germany.

Front Neurol ; 13: 913616, 2022.

Article en En | MEDLINE | ID: mdl-35832177

Palabras clave

medication adherence; medication persistence; observational study; patient-reported outcomes; protocol; real-world evidence; relapsing-remitting multiple sclerosis; trial-in-progress

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Front Neurol Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google